Pierre Fenaux

88.8k citations

869 papers · 36.8k indexed · 6 hit papers · h-index 90

Impact in

Hematology top 0.01%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
Genetics top 0.01%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 696
- Acute Myeloid Leukemia Research 612
- Chronic Myeloid Leukemia Treatments 113
- Multiple Myeloma Research and Treatments 89
Genetics 342
- Myeloproliferative Neoplasms: Diagnosis and Treatment 159
- Chronic Lymphocytic Leukemia Research 132
- Hemoglobinopathies and Related Disorders 86

Co-authors: Claude Preudhomme Christine Chomienne F Bauters Guillermo Sanz Miguel Á. Sanz Lionel Adès Hervé Dombret Sylvie Castaigné
Journals: Blood (275 papers)Leukemia Research (81 papers)Leukemia (54 papers)Journal of Clinical Oncology (53 papers)British Journal of Haematology (52 papers)
Partner nations: France United States Germany

In The Last Decade

Pierre Fenaux

834 papers receiving 35.9k citations

Hit Papers

6 papers align trajectories log scale

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 2009 · 2.4k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 Blood
2009 Journal of Clinical Oncology
2009 The Lancet Oncology
2008 Blood
1997 Blood
1990 Blood

Peers

Countries citing papers authored by Pierre Fenaux

Since Specialization

Citations

This map shows the geographic impact of Pierre Fenaux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Fenaux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Fenaux more than expected).

Fields of papers citing papers by Pierre Fenaux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Fenaux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Fenaux. The network helps show where Pierre Fenaux may publish in the future.

Co-authors

The 25 scholars most cited alongside Pierre Fenaux, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Pierre Fenaux Line = papers co-authored together Pierre Fenaux links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial. Journal of Clinical Oncology ·Guillermo Garcia‐Manero, Karen Yee, Francisca Hernández, Matteo Della Porta, Stefania Paolini, Seo-Yeon Ahn, Valeria Santini, Pierre Fenaux, Takahiro Suzuki, Mikkael A. Sekeres, Jun He, Jerry Li, Ronit Barkalifa, Carlos E. Vigil, Thomas Prébet, Daniel L. Menezes, Joseph W. Burnett, Rami S. Komrokji, Aristoteles Giagounidis	2024	1
2	Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study Blood ·Esther Natalie Olíva, Uwe Platzbecker, Matteo Giovanni Della Porta, Guillermo Garcia‐Manero, Valeria Santini, Pierre Fenaux, Jake Shortt, Rami S. Komrokji, C. Pelligra, Shien Guo, Aylin Yücel, Mrudula B. Glassberg, Laurie Eliason, Ahmed Hnoosh, Dimana Miteva, Shelo Rose, Sandra Kreitz, Mikkael A. Sekeres, Amer M. Zeidan	2024	2
3	Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial. Journal of Clinical Oncology ·Amer M. Zeidan, Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, Guillermo Garcia‐Manero, Jiahui Li, Sandra Kreitz, Veronika Pozharskaya, Shelonitda Rose, Yinzhi Lai, David Valcárcel, Pierre Fenaux, Jake Shortt, Rami S. Komrokji	2024	2
4	Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS). Journal of Clinical Oncology ·Guillermo Garcia‐Manero, Uwe Platzbecker, Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Rami S. Komrokji, Jake Shortt, David Valcárcel, Anna Jonášová, Sophie Dimicoli‐Salazar, Ing Soo Tiong, Chien‐Chin Lin, Jiahui Li, Sandra Kreitz, Veronika Pozharskaya, Jeevan K. Shetty, Andrius Degulys, Carlo Finelli, Thomas Cluzeau, Matteo Giovanni Della Porta	2023	0
5	Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients Leukemia ·Nikolaus Jahn, Maral Saadati, Pierre Fenaux, Marco Gobbi, Gail J. Roboz, Lars Bullinger, Pavlo Lutsik, Anna Riedel, Christoph Plass, Claudia Walter, Karlheinz Holzmann, Yong Hao, Sue Naim, Nicholas Schreck, Julia Krzykalla, Axel Benner, Harold Keer, Mohammad Azab, Konstanze Döhner, Hartmut Döhner	2023	22
6	Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts Leukemia ·Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia‐Manero, Rena Buckstein, Dimana Miteva, Karen L. Keeperman, Natalia Holot, Jose Alberto Nadal, Yinzhi Lai, Sadanand Vodala, Barbara Rosettani, Ana Carolina Giuseppi, Aylin Yücel, Pierre Fenaux	2023	7
7	Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes SHILAP Revista de lepidopterología ·Vincent Jachiet, Pierre Fenaux, Anna Sevoyan, Yervand Hakobyan, Lionel Adès, O. Fain, A. Mékinian, (unknown)	2021	3
8	Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease Leukemia ·Lin‐Pierre Zhao, Maxime Boy, Célia Azoulay, Emmanuelle Clappier, Marie Sébert, Ludivine Amable, Jihène Klibi, Kamel Benlagha, Marion Espéli, Karl Balabanian, Claude Preudhomme, Alice Marceau‐Renaut, Lina Benajiba, Raphaël Itzykson, A. Mékinian, O. Fain, Antoine Toubert, Pierre Fenaux, Nicolas Dulphy, Lionel Adès	2021	25
9	Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis Blood ·Pierre Fenaux, Jean‐Jacques Kiladjian, Uwe Platzbecker	2019	69
10	Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review British Journal of Haematology ·Sophie Park, Peter L. Greenberg, Aylin Yücel, Caroline Farmer, Frank J. O’Neill, Cisio De Oliveira Brandao, Pierre Fenaux	2018	36
11	An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia Clinical Cancer Research ·Françoise Solly, Catherine Koering, Aminetou Mint Mohamed, Delphine Maucort‐Boulch, Guillaume Robert, Patrick Auberger, Pascale Flandrin‐Gresta, Lionel Adès, Pierre Fenaux, Olivier Kosmider, Emmanuelle Tavernier, Jérôme Cornillon, Denis Guyotat, Lydia Campos, Franck Mortreux, Eric Wattel	2016	29
12	Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group Journal of Clinical Oncology ·Cécile Bally, Jehane Fadlallah, Guy Leverger, Yves Bertrand, Alain Robert, André Baruchel, Agnès Guerci, Christian Récher, Emmanuel Raffoux, Xavier Thomas, Thierry Leblanc, Nadia Idres, Bruno Cassinat, Norbert Vey, Christine Chomienne, Hervé Dombret, Miguel Á. Sanz, Pierre Fenaux, Lionel Adès	2012	32
13	Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I / II Study by the GFM British Journal of Haematology ·Shanti Natarajan‐Amé, Sophie Park, Lionel Adès, Norbert Vey, Agnès Guerci‐Bresler, Jean‐Yves Cahn, Gabriel Étienne, Dominique Bordessoule, Christophe Ravoet, Laurence Legros, Stéphane Chèze, Aspasia Stamatoullas, É. Berger, Aline Schmidt, Aude Charbonnier, Marie‐Pierre Chaury, Thorsten Braun, Pierre Fenaux, François Dreyfus, (unknown)	2012	12
14	Neurological disorders in essential thrombocythemia Haematologica ·S. Billot, Eirini Kouroupi, J. Le Guilloux, Bruno Cassinat, Christophe Jardin, Thierry Laperche, Pierre Fenaux, Alain Carpentier, Jean‐Jacques Kiladjian	2011	14
15	Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia Journal of Clinical Oncology ·Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg, Valeria Santini, Norbert Gattermann, Ulrich Germing, Guillermo Sanz, Alan F. List, Steven D. Gore, John F. Seymour, Hervé Dombret, Jay T. Backstrom, Linda Zimmerman, David R. McKenzie, C.L. Beach, Lewis R. Silverman Hit paper breakdown →	2009	698
16	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood ·Hartmut Döhner, Elihu H. Estey, Sergio Amadori, Frederick R. Appelbaum, Thomas Büchner, Alan K. Burnett, Hervé Dombret, Pierre Fenaux, David Grimwade, Richard A. Larson, Francesco Lo‐Coco, Tomoki Naoe, Dietger Niederwieser, Gert J. Ossenkoppele, Miguel Á. Sanz, Jorge Sierra, Martin S. Tallman, Bob Löwenberg, Clara D. Bloomfield Hit paper breakdown →	2009	2350
17	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study Blood ·Lionel Adès, Simone Boehrer, Thomas Prébet, Odile Beyne‐Rauzy, Laurence Legros, Christophe Ravoet, François Dreyfus, Aspasia Stamatoullas, Marie Pierre Chaury, Jacques Delaunay, Laurent Guy, Norbert Vey, Sara Burcheri, Rose-Marie Mbida, Natacha Hoarau, Claude Gardin, Pierre Fenaux	2008	107
18	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases Blood ·Jean‐Jacques Kiladjian, Francisco Cervantes, Frank W.G. Leebeek, Christophe Marzac, Bruno Cassinat, Sylvie Chevret, Dominique Cazals‐Hatem, Aurélie Plessier, Juan Carlos García‐Pagán, Sarwa Darwish Murad, S. Raffa, Harry L.A. Janssen, Claude Gardin, Sophie Cereja, Carole Tonetti, Stéphane Giraudier, Bertrand Condat, Nicole Casadevall, Pierre Fenaux, Dominique Valla	2008	227
19	Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study Blood ·Bertrand Godeau, Raphaël Porcher, Olivier Fain, François Lefrère, Pierre Fenaux, Stéphane Chèze, Anne Vekhoff, Marie‐Paule Chauveheid, Jérôme Stirnemann, Lionel Galicier, Emmanuelle Bourgeois, Stéphanie Haïat, Bruno Varet, M Leporrier, T. Papo, Mehdi Khellaf, Marc Michel, Philippe Bierling	2008	184
20	Délétion chromosomique 17p, mutation de P53, anomalie de Pelger-Huët et vacuolisation des granulocytes : une nouvelle entité dans les pathologies myéloïdes ? Hématologie ·Claude Preudhomme, Marc Zandecki, Jean Luc Laı̈, Pierre Fenaux	1995	1

About Pierre Fenaux

Pierre Fenaux is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Oncology and Molecular Biology, having authored 869 papers that have together received 36.8k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (612 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (159 papers), Chronic Lymphocytic Leukemia Research (132 papers), Retinoids in leukemia and cellular processes (118 papers), Chronic Myeloid Leukemia Treatments (113 papers), Acute Lymphoblastic Leukemia research (107 papers), Multiple Myeloma Research and Treatments (89 papers) and Hemoglobinopathies and Related Disorders (86 papers). The work is most often cited by research in Hematology (27.8k citations), Genetics (11.4k citations), Molecular Biology (15.7k citations), Biochemistry (1.3k citations) and Public Health, Environmental and Occupational Health (5.9k citations). Pierre Fenaux has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Claude Preudhomme, Christine Chomienne, F Bauters, Guillermo Sanz, Miguel Á. Sanz, Lionel Adès, Hervé Dombret, Sylvie Castaigné, Pierre Morel and John M. Bennett. Their work appears in journals such as Blood, Leukemia Research, Leukemia, Journal of Clinical Oncology and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact